Allergopharma and S-TARget therapeutics conclude licensing agreement
Objective is new generation of therapeutics for allergy treatment
04-Sep-2014 -
Allergopharma, the Merck Business Unit Allergy, and S-TARget therapeutics (S-TARget), an Austrian biotechnology company which develops therapeutic preparations for all forms of allergies, have signed an exclusive licensing agreement. The main focus of this cooperation is the use of S-TARget ...
allergies
Merck